TEXT-S&P revises Bristol-Myers Squibb short-term rating to 'A-1+'

Overview
-- Standard & Poor's Ratings Services has revised its criteria regarding
the linkage of issuers' long-term and short-term ratings as they relate to
liquidity.
-- Considering U.S.-based pharmaceutical company Bristol-Myers Squibb's
exceptional liquidity, we are raising our short-term rating on the company to
'A-1+' from 'A-1', based on the new criteria.
-- We are also affirming our 'A+' long-term corporate credit rating on
the company. The long-term rating out

home inspection thermal imaging termite inspection for home purchase energy efficient commercial lighting